Notice of Interim Results

RNS Number : 7548A

Ergomed plc

14 September 2018

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

Notice of Interim Results

London, UK - 14 September 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ended 30 June 2018 on Wednesday 19^th September 2018.

Stephen Stamp, Chief Executive Officer and Stuart Jackson, Chief Financial Officer, will host a presentation and conference call for analysts at 8:30am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Stephen Stamp (Chief Executive Officer) Stuart Jackson (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
Consilium Strategic Communications - for UK enquiries		Tel: [phone]
Chris Gardner / Mary-Jane Elliott Matthew Neal / Olivia Manser	[e-mail]
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

END

 

 

NORDBGDCUBBBGIX